v2.4.0.8

Quarterly Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 28, 2013
Quarterly Financial Data [Abstract] |
Quarterly Information (Unaudited) | Note 18 – Quarterly Information (Unaudited) The following tables present certain quarterly financial data:
|  |  | Quarters ended
|  |  | March 30, |  | June 29, |  | September 28, |  | December 28,
|  |  | 2013 (1) |  | 2013 |  | 2013 (2) (3) |  | 2013
Net sales |  | $ | 2,293,511 |  | $ | 2,391,810 |  | $ | 2,348,956 |  | $ | 2,526,370
Gross profit |  |  | 646,991 |  |  | 669,856 |  |  | 639,647 |  |  | 699,520
Operating income |  |  | 153,629 |  |  | 176,065 |  |  | 160,477 |  |  | 186,883
Net income |  |  | 98,686 |  |  | 121,435 |  |  | 116,372 |  |  | 134,969
Amounts attributable to |  |  |  |  |  |  |  |  |  |  |  |
| Henry Schein, Inc.: |  |  |  |  |  |  |  |  |  |  |  |
Net income |  |  | 91,478 |  |  | 108,430 |  |  | 107,378 |  |  | 124,268
Earnings per share attributable to |  |  |  |  |  |  |  |  |  |  |  |
| Henry Schein, Inc.: |  |  |  |  |  |  |  |  |  |  |  |
| Basic |  | $ | 1.06 |  | $ | 1.26 |  | $ | 1.25 |  | $ | 1.46
| Diluted |  |  | 1.03 |  |  | 1.23 |  |  | 1.23 |  |  | 1.43
|  |  | Quarters ended
|  |  | March 31, |  | June 30, |  | September 29, |  | December 29,
|  |  | 2012 (4) |  | 2012 |  | 2012 |  | 2012
Net sales |  | $ | 2,099,019 |  | $ | 2,201,452 |  | $ | 2,231,058 |  | $ | 2,408,438
Gross profit |  |  | 610,579 |  |  | 624,395 |  |  | 609,044 |  |  | 663,495
Operating income |  |  | 133,295 |  |  | 154,702 |  |  | 149,622 |  |  | 181,342
Net income |  |  | 89,061 |  |  | 107,302 |  |  | 105,310 |  |  | 121,715
Amounts attributable to |  |  |  |  |  |  |  |  |  |  |  |
| Henry Schein, Inc.: |  |  |  |  |  |  |  |  |  |  |  |
Net income |  |  | 80,752 |  |  | 98,086 |  |  | 96,771 |  |  | 112,467
Earnings per share attributable to |  |  |  |  |  |  |  |  |  |  |  |
| Henry Schein, Inc.: |  |  |  |  |  |  |  |  |  |  |  |
| Basic |  | $ | 0.92 |  | $ | 1.11 |  | $ | 1.11 |  | $ | 1.29
| Diluted |  |  | 0.89 |  |  | 1.08 |  |  | 1.08 |  |  | 1.26
(1) | See Note 5 - "Debt" for details of expenses related to the refinancing of HSAH debt incurred during the first quarter
| of 2013.
(2) | See Note 9 - "Business Acquisitions, Divestiture and Other Transaction" for details of the loss on sale of equity
| investment incurred during the third quarter of 2013.
(3) | See Note 12 - "Incomes Taxes" for details of the reduction of our valuation allowance related to certain deferred tax
| assets incurred during the third quarter of 2013.
(4) | See Note 10 - "Plans of Restructuring" for details of the restructuring costs incurred during the first quarter of 2012.
We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations of securities analysts and investors, which could cause our stock price to decline. Our business is subject to seasonal and other quarterly fluctuations. Net sales and operating profits generally have been higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza vaccine, equipment and software products), purchasing patterns of office-based health care practitioners and year-end promotions. Net sales and operating profits generally have been lower in the first quarter, primarily due to increased sales in the prior two quarters. We expect our historical seasonality of sales to continue in the foreseeable future. Quarterly results also may be adversely affected by a variety of other factors, including: • timing and amount of sales and marketing expenditures; • timing of pricing changes offered by our vendors; • timing of the introduction of new products and services by our vendors; • timing of the release of upgrades and enhancements to our technology-related products and services; • changes in or availability of vendor contracts or rebate programs; • vendor rebates based upon attaining certain growth goals; • changes in the way vendors introduce or deliver products to market; • costs of developing new applications and services; • our ability to correctly identify customer needs and preferences and predict future needs and preferences; • exclusivity requirements with certain vendors may prohibit us from distributing competitive products manufactured by other vendors; • loss of sales representatives; • costs related to acquisitions and/or integrations of technologies or businesses; • costs associated with our self-insured medical and dental insurance program s; • general market and economic conditions, as well as those specific to the health care industry and related industries; • our success in establishing or maintaining business relationships; • unexpected difficulties in developing and manufacturing products; • product demand and availability or recalls by manufacturers; • exposure to product liability and other claims in the event that the use of the products we sell resul ts in injury; • increases in the cost of shipping or service issue s with our third-party shippers; • restructuring costs; and • changes in accounti ng principles. Any change in one or more of these or other factors could cause our annual or quarterly operating results to fluctuate. If our operating results do not meet market expectations, our stock price may decline.

X
- Details
Name: | us-gaap_QuarterlyFinancialDataAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=25249566&loc=d3e1280-108306 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section G -Subsection 1 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 302 -Paragraph a + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration